OCLG.. Nice recent 8k... over 3 mil in revenues latest quarter... 750 Mil A/S at .0004
On November 23, 2016, Oncologix Tech, Inc. ( the “Company”) signed Amendment #1 to our series B Convertible Stock Purchase Agreement. This amendment outlines a new funding/investment schedule by Diversified Innovative Marketing Enterprises, Ltd. (“DIMEVC”). The new amendment calls for monthly investments of $200,000 beginning December 20, 2016 and continuing for five (5) months. Following those initial tranches, a $4,000,000 investment is expected to be delivered on May 19, 2017 with the final $5,000,000 tranche to be delivered on June 23, 2017. Should any tranche not be met, this Agreement terminates “For Cause” and the Company reserves the right to seek legal remedy for potential damages.
Mr. Erwin will remain with the Company and will serve as President of the Company’s operating subsidiaries and will work in that capacity to focus his efforts to expand our client base and various product lines.
Mr. Kramarz, has been with the Company since 2002 and along with Mr. Halman will continue to work with Mr. Erwin to expand the Company’s foot-print to increase Shareholder value.
